Investing.com - Reneo Pharmaceuticals (NASDAQ: RPHM) reported first quarter EPS of $-0.600, better than the analyst estimate of $-0.608. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Reneo Pharmaceuticals's stock price closed at $7.980. It is up 165.120% in the last 3 months and up 299.060% in the last 12 months.
Reneo Pharmaceuticals saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Reneo Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Reneo Pharmaceuticals's Financial Health score is "fair performance".
Check out Reneo Pharmaceuticals's recent earnings performance, and Reneo Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar